COMPASS PATHWAYS PLC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
COMPASS PATHWAYS PLC (CMPS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 2.58 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-24
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-03-31 was 2.07M shares, a 0.16% decline year-over-year.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-12-31 was 48.75K shares, a 59.38% decline year-over-year.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-09-30 was 146.30K shares, a 81.31% decline year-over-year.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2023-06-30 was 288.92K shares.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.58M shares, a 13.20% decline from fiscal 2024.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.97M shares, a 16.15% increase from fiscal 2023.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.56M shares, a 20.75% increase from fiscal 2022.
- COMPASS PATHWAYS PLC share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 2.12M shares, a 103.20% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2025-12-31 | 2.58M shares 10-K · filed 2026-03-24 | |||
| 2024-12-31 | 2.97M shares 10-K · filed 2025-02-27 | |||
| 2024-03-31 | 2.07M shares 10-Q · filed 2024-05-08 | 2.12M shares derived: sum of 2 quarters · filed 2024-05-08 | 2.27M shares derived: sum of 3 quarters · filed 2024-05-08 | 2.56M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 48.75K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 195.05K shares derived: sum of 2 quarters · filed 2024-02-29 | 483.97K shares derived: sum of 3 quarters · filed 2024-02-29 | 2.56M shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 146.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 435.22K shares derived: sum of 2 quarters · filed 2023-11-02 | 2.51M shares 10-Q · filed 2023-11-02 | 2.63M shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | 288.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 2.37M shares 10-Q · filed 2023-08-03 | 2.49M shares derived: sum of 3 quarters · filed 2023-08-03 | 3.27M shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 2.08M shares 10-Q · filed 2023-05-11 | 2.20M shares derived: sum of 2 quarters · filed 2023-05-11 | 2.98M shares derived: sum of 3 quarters · filed 2023-05-11 | |
| 2022-12-31 | 120.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 902.97K shares derived: sum of 2 quarters · filed 2023-02-28 | 2.12M shares 10-K · filed 2023-02-28 | |
| 2022-09-30 | 782.97K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 2.00M shares 10-Q · filed 2022-11-03 | ||
| 2022-06-30 | 1.22M shares 10-Q · filed 2022-08-04 | |||
| 2021-12-31 | 1.04M shares 10-K · filed 2023-02-28 | |||
| 2021-06-30 | 102.05K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 312.13K shares 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | 210.08K shares 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |